Stephen T. Oh, MD, PhD, concludes with thoughts on the future treatment landscape for myelofibrosis.
Case: A 63-Year-Old Man with Myelofibrosis
Clinical Presentation:
Follow up and Clinical Workup at 3 Months:
Follow up and Clinical Workup at 6 Months:
FDA Enforces Partial Hold on Trial of Seclidemstat in MDS/CMML
July 16th 2024Following the report of a serious and unexpected grade 4 adverse effect, a partial clinical hold has been placed on the phase 1 trial evaluating seclidemstat with azacitidine in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Read More